Document Detail


What is the value for money of medicines? A registry study.
MedLine Citation:
PMID:  21812796     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
WHAT IS KNOWN AND OBJECTIVE: Economic evaluation is used to assess the value for money of medicines and inform pharmaceutical pricing/reimbursement decisions in many countries. This paper aims to report on estimates of the value for money of medicines in Europe.
METHODS: Estimated cost-utilities were derived from studies included in the Tufts Medical Center Cost-Effectiveness Analysis Registry between 2000 and 2007. For each study, the following variables were examined: publication year, target population, intervention type, country of patient sample, disease classification, prevention stage, funding source, study perspective, discounting, sensitivity analysis, incremental cost-utility ratio (ICUR) and methodological quality.
RESULTS AND DISCUSSION: Six hundred and eight ICURs were reported in 231 cost-utility analyses. Around 17·1% of ratios related to medicines that were more effective and less expensive than the comparator; 76·5% related to medicines that improved outcomes, but increased costs; and 6·4% related to medicines that were less effective and more expensive than the comparator. The median ratio was 12,238 € per quality-adjusted life year (QALY). Using threshold values of 20,000 and 50,000 € per QALY, the probability that medicines provided value for money was 58% and 81%, respectively. Preventive medicines studied provided more value for money than curative medicines (P=0·002). Studies sponsored by industry generated more favourable results than studies sponsored from other sources (P<0·001). However, no association was observed between the funding source and the methodological quality of economic evaluations.
WHAT IS NEW AND CONCLUSION: The evidence base suggests that the majority of medicines provided value for money. Such information informs policy decisions relating to the allocation of scarce health care resources in Europe.
Authors:
S Simoens
Related Documents :
21731526 - National oncology practice benchmark: an annual assessment of financial and operational...
12463936 - Understanding usage patterns of handheld computers in clinical practice.
21883636 - The academic chair in emergency medicine: current demographics and survey results ident...
20369156 - Are general practice networks 'ready' for clinical data management?
20576776 - The effect of recent amblyopia research on current practice in the uk.
3688146 - The art of leading meetings.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2011-08-04
Journal Detail:
Title:  Journal of clinical pharmacy and therapeutics     Volume:  37     ISSN:  1365-2710     ISO Abbreviation:  J Clin Pharm Ther     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-03-06     Completed Date:  2012-06-25     Revised Date:  2014-07-30    
Medline Journal Info:
Nlm Unique ID:  8704308     Medline TA:  J Clin Pharm Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  182-6     Citation Subset:  IM    
Copyright Information:
© 2011 Blackwell Publishing Ltd.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cost-Benefit Analysis
Decision Making
Drug Costs*
Europe
Health Policy
Humans
Pharmaceutical Preparations / economics*
Quality-Adjusted Life Years*
Registries
Research Design / standards
Chemical
Reg. No./Substance:
0/Pharmaceutical Preparations

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparison of media formulations used to selectively cultivate Dekkera/Brettanomyces.
Next Document:  Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patient...